(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

10/528691

(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029046 A2

(51) International Patent Classification[7]: C07D 409/00

(21) International Application Number:
PCT/DK2003/000645

(22) International Filing Date:
30 September 2003 (30.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 01450 30 September 2002 (30.09.2002) DK

(71) Applicant *(for all designated States except US)*: A/S GEA FARMACEUTISK FABRIK [DK/DK]; Kanalholmen 8-12, DK-2650 Hvidovre (DK).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: KARUP, Gunnar, Leo [DK/DK]; Bremensgade 39, DK-2300 Copenhagen S (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvej 7, DK-2650 Hvidovre (DK).

(74) Agents: RASMUSSEN, Preben et al.; Internationalt Patent-Bureau A/S, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).

(81) Designated States *(national)*: AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,*

[Continued on next page]

(54) Title: NOVEL RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF, IMPROVED METHOD FOR PURIFICATION OF SAID RALOXIFENE ACID ADDITION SALTS AND/OR SOLVATES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE



(57) Abstract: Raloxifene acid addition salts or solvates thereof, having improved dissolution properties in media comprising hydrochloric acid are described, compared with similar preparations based on raloxifene or raloxifene hydrochloride. The disclosed acid addition salts or solvates thereof show an improved bioavailability in media comprising hydrochloric acid, such as the gastric juice. The acid addition salts or solvates thereof are addition salts or solvates of raloxifene and a pharmaceutical acceptable acid selected among succinic acid, lactic acid, malonic acid or sulphuric acid. Further, crystalline forms of the raloxifene salts and solvates thereof are disclosed. The raloxifene acid addition salts and/or solvates thereof are useful for the preparation of pharmaceutical composition for oral administration capable of fast and reliable release of the active ingredients in the stomach of the patient, in particular for the treatment of cancer or osteoporosis, or for inhibiting cartilage degradation. A new method for preparation of raloxifene lactate is also disclosed.

WO 2004/029046 A2